In advanced myelodysplastic syndrome (MDS) and secondary acute myeloid leukemia (sAML), aberrant methylation targets genes involved in apoptosis, cell cycle, DNA repair or adherence, or silencing tumor suppressor genes. [1] [2] [3] The correlation between DNA hypermethylation and disease progression provides a rationale for the therapeutic use of Dnmt inhibitors. Azacitidine induces a hematological response in 40-50% of high-risk (HR)-MDS patients, delays the disease progression to sAML and significantly prolongs overall survival. 4 FAS/TNFRSF6/APO1 that belongs to a set of genes involved in the control of apoptosis is hypermethylated in tumors. [5] [6] [7] We have previously shown that Fas is overexpressed in low/int-1-risk (LR)-MDS. 8 Conversely, decreased expression of pro-apoptotic Fas, or Fas-associated via death domain (FADD) or increased anti-apoptotic Bcl2 protein in int-2 or HR-MDS could participate in resistance to apoptosis and contribute to disease progression.
Consecutive patients (n ¼ 169) with a WHO diagnosis of MDS (n ¼ 136), including 33 refractory anemia (RA)/refractory cytopenia (RC)/MDS-unclassified (MDS-U), 9 5q-, 17 RC with multilineage dysplasia (RCMD), 30 RA with ring sideroblasts (RARS)/RCMD with ring sideroblasts (RCMD-RS), 32 RA with excess of blasts (RAEB)-1, 15 RAEB-2, or 33 sAML and 25 age-matched controls with normal bone marrow (BM) were recorded between 2005 and 2011 for flow cytometry analysis of Fas expression on BM CD45 lo /CD34 þ cell population. The median ratio of fluorescence intensity (RFI) was significantly increased in LR-MDS (n ¼ 104) or HR-MDS (n ¼ 32) compared with a control group, and lower in sAML compared with LR-MDS or HR-MDS (Figure 1a ). Sequential analysis of Fas expression in 26 MDS patients whose disease had progressed identified a significant decrease of the median Fas RFI from 2.1 (interquartile range (IQR) 25-75%: 1.8-2.8) at diagnosis to 1.2 (IQR 25-75%: 1.0-1.8) at later time points (Student t-test; P ¼ 0.003), whereas the median percentage of blasts concomitantly increased from 5 (4-9) to 18% (12-24; Po0.0001; Supplementary Table S1 ). The threshold of Fas protein expression positivity predictive of MDS, deduced from a receiver operating characteristics analysis of Fas expression, was an RFI of 1.8.
We then investigated whether the FAS gene expression was epigenetically regulated along the MDS disease progression to AML. Variations of the methylation level at FAS promoter have already been described in one CpG island located over the transcription start site ( þ 1) and in a 5 0 -regulatory region located upstream the CpG island in the NIH3T3 cell line transformed by KRAS or in primary tumor cells. [5] [6] [7] 9 Thus, we extensively studied DNA methylation of the promoter region spanning between À 899 and þ 231, which contains 35 CpG dinucleotides, of which 26 belong to a CpG island. The FAS promoter was amplified from bisulfite-treated genomic DNA extracted from CD34 þ cells in 18 LR-MDS, 8 HR-MDS, 11 sAML and 8 controls (Supplementary  Table S2 for primers). The PCR products were cloned in bacteria, and at least eight clones per case were sequenced. Global level of methylation expressed as the percentage of methylated CpG at each dinucleotide was significantly higher in sAML compared with LR-MDS (P ¼ 0.01), HR-MDS (P ¼ 0.008), and LR-or HR-MDS Tables  S3 and S4 ). Responses were scored according to the International Working Group (IWG) 2006 criteria for MDS. 10 Patients having stable disease with hematological improvement (HI) were considered as responders, and those without HI were considered as non-responders. Flow cytometry analysis of Fas was performed in 38 patients (13 sAML and 25 MDS) at diagnosis, just before treatment initiation and after X3 cycles of treatment (Supplementary  Table S4 and Figure 1d ). Before treatment, the mean Fas RFI was higher in MDS (1.9 ± 0.6) than in sAML (1.6 ± 0.4) patients. An increase in Fas protein expression on BM CD45 lo /CD34 þ blast cells was observed in 25 out of 38 patients upon therapy. In 13 patients with HR-MDS or sAML, the percentage of methylated CpG at FAS promoter decreased by 30-100% after X3 cycles of azacitidine (Supplementary Figure S1) . Among these 38 patients, 23 patients responded to azacitidine treatment with a significant decrease of BM blast percentages (Po0.012). The median RFI value for Fas was 1.3 (IQR 25-75%: 1.2-1.5) and 2.8 (IQR 25-75%: 2.0-3.0) before and after treatment, respectively (Figure 1e, Student's t-test; Po0.001). By contrast, the difference of Fas RFI between baseline and post therapy was not significant in the 15 non-responders (Figure 1e) . Then, we investigated the impact of Fas expression at diagnosis on the response to treatment. In the cohort of 63 patients, the median number of cycles was 6 (3-8) and the follow-up after initiation of treatment was 10.2 months (IQR 25-75%: 4.9-14.3). The two groups separated on the basis of positive (RFIX1.8) or negative (RFIo1.8) Fas protein expression at diagnosis presented with no particular differences in clinical and biological characteristics (Supplementary Table S3 ). Previous treatments included best supportive care in 60 patients, lenalidomide/thalidomide in 8 patients, intensive chemotherapy or allogeneic stem cell transplantation in 9 patients and decitabine in 1 patient, and 17 patients had received no previous therapy. According to the IWG criteria, complete remission (CR), partial remission (PR) and HI were achieved in 16, 15 and 2 patients, respectively. Seven patients had a stable disease without HI and the treatment failed in 22 patients. One patient was non-evaluable (Supplementary  Table S4) . Kaplan-Meier analysis demonstrated that a low Fas protein expression correlated with a better response rate, including CR, PR and HI (log-rank test; P ¼ 0.005; Figure 1f ). Multivariate analysis showed that a high Fas expression on CD45 lo /CD34 þ cells at diagnosis was predictive of failure of azacitidine treatment with a hazard ratio of 2.75 (95% confidence interval: 1.13-6.69; log-rank test, P ¼ 0.026), independently of International Prognosis Scoring System (IPSS), age or prior therapy. IPSS remained the sole significant predictor of overall survival in this cohort (Table 1) . Thus, a low Fas expression at diagnosis is a biomarker of the response to azacitidine.
The present study demonstrates that FAS gene is epigenetically repressed in BM progenitors of MDS patients when disease progresses to sAML due to promoter hypermethylation. At transcript level, we have found that FAS, FADD and BAX/ BCL2L4, but not CASP8/FLICE or FASLG/TNFSF6, were significantly downregulated in HR-MDS compared with LR-MDS. Altogether, variations in apoptotic gene expression may contribute to disease progression through inducing resistance to apoptosis. C2  C3  C4  C5  C6  C7  C8  10  11  13  18  19  26  28  35  52  56  63  64  65  68  70  78  82  90  2  7  8  36  37  50  55  85  1  5  12  17  31  34  53  62  76  77 þ at baseline by flow cytometry. Filled line represents Fas-negative patients (RFIo1.8) and dotted line represents Fas-positive patients (RFIX1.8; log-rank test for P-value). Abbreviations: sAML, secondary acute myeloid leukemia; CI, confidence interval; HR, high risk; IPSS, International Prognosis Scoring System; MDS, myelodysplastic syndrome. Age is indicated as 10-year increment. Risk linked to prior therapy is considered for erythropoiesis-stimulating agent (ESA), lenalidomide/thalidomide and intensive chemotherapy. Log-rank test for P-values.
Letters to the editor
In other hematopoietic cells like neoplastic mast cells 7 or non-hematopoietic tumor cells, FAS, CASP8, BAX, CASP1, APAF1 or DAPK1 can be aberrantly methylated. 7, 11 The mechanism by which FAS promoter is overmethylated in sAML is still unclear. However, the 5 0 -CpG1-8 are located immediately downstream of the docking site of Dnmt1, which promotes FAS promoter methylation in KRAS-transformed NIH3T3 cells. 9 Targeting Dnmt by the use of specific inhibitors like azacitidine or decitabine supports DNA methylation reversal throughout the genome, and rescues apoptosis and/or differentiation of leukemic cell lines. Indeed, azacitidine favors the re-expression of FAS in neoplastic mast cells or PI-PLCbeta1 genes in MDS or sAML. 7, 12 Here we show that the in vivo use of the drug also favors the re-appearance of Fas receptor in sAML-derived CD45 lo /CD34 þ cells, together with FAS promoter demethylation (Supplementary Figure S1) .
Fas re-expression upon azacitidine therapy is mainly observed in responder patients. Several predictors of the response to demethylating agents have been proposed, including MDS duration before therapy, prior therapy or previous low doses of aracytine, BM blasts 415%, abnormal karyotype, p15 INK4B gene promoter methylation or hypermethylation of a set of 10 different genes. 13, 14 However, changes in CDKN2B, CDH1, DAPK1 and SOCS-1 gene expression upon therapy did not correlate with the response. 15 Our results show that Fas re-expression correlated with the response and that low Fas protein expression at diagnosis, which associated with hypermethylation of the FAS gene promoter, is a predictive biomarker of the response to azacitidine, independently of IPSS and prior therapy, even if the re-activation of Fas may not be the sole determinant of the response. By contrast, Fas level at diagnosis had no impact on the overall survival. Absence of significant survival benefit in low Fas patients was probably not because of their having shorter median duration of the response, as Fas-negative patients did not achieve the median over the time of observation, but rather to the relatively small number of patients and/or insufficient follow-up.
Aberrant methylation of the FAS gene promoter characterizes MDS progression to sAML and predicts a favorable response to azacitidine. Prospective studies including larger cohorts of patients are warranted to determine whether higher response rate of patients with low Fas expression translates into improved survival.
